PolyPid's drug-delivery tech combines polymers and lipids

PolyPid, an Israeli drug-delivery company, has introduced a new family of drug carriers based on a melding of two drug delivery systems: polymers and lipid-based systems. The PolyPid carrier carrier can be tailored to small molecules, peptides, protein and nucleic acids-based drugs.

The company's technology ensnares a large variety of one or more biologically active molecules and releases them at a pre-programmed rate for up to several months. PolyPid produces a product called BonyPid, a biodegradable bone void filler. After BonyPid releases its coating, over time, the bone void filler scaffold remains and supports bone recovery. This way, according to the company, physicians can "obtain the benefits of conventional bone void filler combined with an effective local drug delivery system."

"Due to its flexibility, the PolyPid platform can be utilized to address numerous medical indications in various fields, such as orthopedics, urology, periodontal, anti-cancer/anti-fungal treatments and surgical accessories," PolyPid CTO Noam Emanuel said in a news release.

- read PolyPid's release
- and a brief report on PBR

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.